PT1326616E - Utilizacao de quetiapina para o disturbio de defice de atencao com hiperactividade ou disturbio de conduta - Google Patents
Utilizacao de quetiapina para o disturbio de defice de atencao com hiperactividade ou disturbio de condutaInfo
- Publication number
- PT1326616E PT1326616E PT01961576T PT01961576T PT1326616E PT 1326616 E PT1326616 E PT 1326616E PT 01961576 T PT01961576 T PT 01961576T PT 01961576 T PT01961576 T PT 01961576T PT 1326616 E PT1326616 E PT 1326616E
- Authority
- PT
- Portugal
- Prior art keywords
- conduct
- disturbent
- quetiapine
- hyperactivity
- disturbing
- Prior art date
Links
- 230000007812 deficiency Effects 0.000 title 1
- 208000013403 hyperactivity Diseases 0.000 title 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 title 1
- 229960004431 quetiapine Drugs 0.000 title 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000027691 Conduct disease Diseases 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D281/16—[b, f]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0003126A SE0003126D0 (sv) | 2000-09-05 | 2000-09-05 | Method of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1326616E true PT1326616E (pt) | 2005-06-30 |
Family
ID=20280890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT01961576T PT1326616E (pt) | 2000-09-05 | 2001-08-31 | Utilizacao de quetiapina para o disturbio de defice de atencao com hiperactividade ou disturbio de conduta |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7338948B2 (enExample) |
| EP (1) | EP1326616B1 (enExample) |
| JP (1) | JP2004508333A (enExample) |
| AT (1) | ATE291920T1 (enExample) |
| AU (1) | AU2001282832A1 (enExample) |
| DE (1) | DE60109799T2 (enExample) |
| ES (1) | ES2238469T3 (enExample) |
| PT (1) | PT1326616E (enExample) |
| SE (1) | SE0003126D0 (enExample) |
| WO (1) | WO2002020019A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006073360A1 (en) * | 2005-01-07 | 2006-07-13 | Astrazeneca Ab | NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f] [1,4] THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS |
| US20090035370A1 (en) * | 2007-08-02 | 2009-02-05 | Drugtech Corporation | Dosage form and method of use |
| GB0822077D0 (en) * | 2008-12-03 | 2009-01-07 | Minster Res Ltd | Novel treatments |
| US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US5605897A (en) | 1991-04-23 | 1997-02-25 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine |
| US5627178A (en) | 1991-04-23 | 1997-05-06 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| GB9611328D0 (en) * | 1996-05-31 | 1996-08-07 | Zeneca Ltd | Pharmaceutical compositions |
-
2000
- 2000-09-05 SE SE0003126A patent/SE0003126D0/xx unknown
-
2001
- 2001-08-31 PT PT01961576T patent/PT1326616E/pt unknown
- 2001-08-31 DE DE60109799T patent/DE60109799T2/de not_active Expired - Fee Related
- 2001-08-31 WO PCT/SE2001/001879 patent/WO2002020019A1/en not_active Ceased
- 2001-08-31 AT AT01961576T patent/ATE291920T1/de not_active IP Right Cessation
- 2001-08-31 ES ES01961576T patent/ES2238469T3/es not_active Expired - Lifetime
- 2001-08-31 JP JP2002524503A patent/JP2004508333A/ja not_active Abandoned
- 2001-08-31 EP EP01961576A patent/EP1326616B1/en not_active Expired - Lifetime
- 2001-08-31 US US10/398,307 patent/US7338948B2/en not_active Expired - Fee Related
- 2001-08-31 AU AU2001282832A patent/AU2001282832A1/en not_active Abandoned
-
2008
- 2008-01-10 US US11/972,350 patent/US20080108597A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60109799D1 (de) | 2005-05-04 |
| JP2004508333A (ja) | 2004-03-18 |
| US20080108597A1 (en) | 2008-05-08 |
| EP1326616B1 (en) | 2005-03-30 |
| EP1326616A1 (en) | 2003-07-16 |
| ES2238469T3 (es) | 2005-09-01 |
| US20040034010A1 (en) | 2004-02-19 |
| ATE291920T1 (de) | 2005-04-15 |
| AU2001282832A1 (en) | 2002-03-22 |
| WO2002020019A1 (en) | 2002-03-14 |
| SE0003126D0 (sv) | 2000-09-05 |
| DE60109799T2 (de) | 2006-02-16 |
| HK1056120A1 (en) | 2004-02-06 |
| US7338948B2 (en) | 2008-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1143967E (pt) | Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas | |
| DK1754707T3 (da) | Multicykliske forbindelser og anvendelse deraf som inhibitorer af PARP-, VEGFR2- og MLK3-enzymer | |
| PT1347971E (pt) | Inibidores tiazolilicos de tirosina-cinases da familia tec | |
| EP1463531A4 (en) | PROCESS FOR INHIBITING OKULAR PROCESSES | |
| DK1446387T3 (da) | Substituerede aryl, 1,4-pyrazinderivater | |
| DE60142590D1 (de) | Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen | |
| DE59902314D1 (de) | Oligomerisiertes Organopolysiloxan-Cokondensat, dessen Herstellung und dessen Verwendung zur Behandlung von Oberflächen | |
| ATE296634T1 (de) | (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen | |
| HUP0104688A2 (hu) | Összetételek és eljárások a rákbetegség és a rákbetegséggel kapcsolódó csontveszteség megelőzéséhez és kezeléséhez | |
| EA200400235A1 (ru) | Комбинированная терапия для лечения рака | |
| UY24949A1 (es) | Compuestos calcilíticos | |
| BG105112A (bg) | Средство с антидепресивно действие | |
| DE60122368D1 (de) | Verwendung von Gaboxadol zur Behandlung von premenstruelle Störung, postnatal Depression oder postmenopausal-bedingte-dysphorische Störung | |
| DE60233350D1 (de) | IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES | |
| DE60206289D1 (de) | Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne | |
| ATE404208T1 (de) | Uridin-therapie für patienten mit erhöhten purin- werten | |
| BR0209883A (pt) | Uso de inibidores da proteasoma para o tratamento de distúrbios do olho seco | |
| PT1326616E (pt) | Utilizacao de quetiapina para o disturbio de defice de atencao com hiperactividade ou disturbio de conduta | |
| ATE383874T1 (de) | Perylenequinonen zur anwendung als sonosensitizer | |
| BRPI0508084A (pt) | método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo | |
| TR200200278T2 (tr) | Kalsilitik bileşimler | |
| DE60117122D1 (de) | Verwendung von mirtazapin zur behandlung von schlafstörungen | |
| ATE426678T1 (de) | Ammoniumsulfat zur aufhebung von inhibitorischen effekten | |
| ATE345818T1 (de) | S-methyl-dihydro-ziprasidone zur behandlung von psychiatrischen störungen. | |
| DE60116478D1 (de) | Verwendung von cdp-cholin zur prophylaxe der cerebralen ischämie |